IRIS Institutional Research Information System - OPENBS Open Archive UniBS

ANDREOLI, Laura
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.765
EU - Europa 7.836
AS - Asia 7.644
SA - Sud America 1.744
AF - Africa 238
OC - Oceania 22
Continente sconosciuto - Info sul continente non disponibili 17
AN - Antartide 1
Totale 31.267
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.520
SG - Singapore 2.644
DE - Germania 2.251
CN - Cina 2.241
BR - Brasile 1.451
UA - Ucraina 1.201
HK - Hong Kong 988
IT - Italia 967
PL - Polonia 776
RU - Federazione Russa 633
VN - Vietnam 620
FI - Finlandia 457
FR - Francia 453
GB - Regno Unito 404
TR - Turchia 303
IE - Irlanda 239
BD - Bangladesh 217
IN - India 178
CA - Canada 116
AR - Argentina 109
SE - Svezia 89
MX - Messico 78
ZA - Sudafrica 73
NL - Olanda 71
IQ - Iraq 65
EC - Ecuador 52
JP - Giappone 51
ID - Indonesia 47
ES - Italia 45
NG - Nigeria 39
AT - Austria 38
PK - Pakistan 38
CO - Colombia 34
SA - Arabia Saudita 33
CZ - Repubblica Ceca 31
VE - Venezuela 30
UZ - Uzbekistan 27
MA - Marocco 26
EG - Egitto 23
AU - Australia 21
BE - Belgio 21
JO - Giordania 21
PY - Paraguay 20
AE - Emirati Arabi Uniti 18
CL - Cile 18
PH - Filippine 17
DZ - Algeria 16
CH - Svizzera 15
EU - Europa 15
KE - Kenya 15
GR - Grecia 14
JM - Giamaica 14
PE - Perù 14
TH - Thailandia 14
HR - Croazia 13
KZ - Kazakistan 13
LT - Lituania 13
AL - Albania 12
PT - Portogallo 12
IL - Israele 11
MK - Macedonia 10
NP - Nepal 10
DK - Danimarca 9
ET - Etiopia 9
RS - Serbia 9
TN - Tunisia 9
UY - Uruguay 9
SK - Slovacchia (Repubblica Slovacca) 8
BG - Bulgaria 7
GE - Georgia 7
HU - Ungheria 7
LY - Libia 7
RO - Romania 7
AZ - Azerbaigian 6
BH - Bahrain 6
CR - Costa Rica 6
DO - Repubblica Dominicana 6
HN - Honduras 6
KR - Corea 6
LB - Libano 6
MY - Malesia 6
PS - Palestinian Territory 6
BB - Barbados 5
BO - Bolivia 5
KG - Kirghizistan 5
KW - Kuwait 5
LU - Lussemburgo 5
SN - Senegal 5
SY - Repubblica araba siriana 5
TW - Taiwan 5
BY - Bielorussia 4
CI - Costa d'Avorio 4
IR - Iran 4
KH - Cambogia 4
LV - Lettonia 4
NO - Norvegia 4
SV - El Salvador 4
AM - Armenia 3
GT - Guatemala 3
LK - Sri Lanka 3
Totale 31.224
Salva come PNG Salva come JPEG
Città #
Fairfield 1.489
Singapore 1.363
Ashburn 1.193
Woodbridge 1.174
Hong Kong 980
Houston 836
Jacksonville 831
Warsaw 766
San Jose 609
The Dalles 574
Seattle 569
Cambridge 544
Wilmington 512
Ann Arbor 491
Beijing 472
Princeton 439
New York 415
Chandler 346
Helsinki 291
Los Angeles 254
Istanbul 243
Dublin 238
Lauterbourg 234
Nanjing 227
Ho Chi Minh City 200
Munich 149
São Paulo 144
Brescia 136
Dallas 135
Hanoi 133
Milan 119
Moscow 117
Redondo Beach 107
San Diego 103
Nanchang 102
Nürnberg 102
Buffalo 101
Des Moines 94
Council Bluffs 89
Changsha 86
Shanghai 83
San Francisco 82
Chicago 79
Shenyang 69
Santa Clara 66
Hebei 65
London 64
Lancaster 63
Orem 52
Rio de Janeiro 52
Turku 52
Nuremberg 51
Tokyo 46
Chennai 44
Jinan 43
Johannesburg 39
Abuja 37
Rome 36
Toronto 36
Hangzhou 35
Tianjin 35
Belo Horizonte 34
Atlanta 33
Denver 33
Bergamo 32
Dearborn 32
Jiaxing 32
Brooklyn 31
Porto Alegre 29
Guangzhou 28
Haiphong 28
Mexico City 28
Poplar 28
Zhengzhou 28
Amsterdam 27
Curitiba 27
Da Nang 27
Frankfurt am Main 27
Dhaka 26
Phoenix 26
Brasília 25
Manchester 25
Tashkent 25
Verona 25
Dong Ket 24
Biên Hòa 23
Montreal 23
Romola 23
Boardman 22
Kunming 21
Amman 19
Baghdad 19
Brussels 19
Guayaquil 19
Brno 18
Lanzhou 18
Mumbai 18
Stockholm 18
Charlotte 16
Goiânia 16
Totale 19.108
Salva come PNG Salva come JPEG
Nome #
9A.07: CARDIOVASCULAR TARGET ORGAN DAMAGE IN PREMENOPAUSAL SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS AND IN CONTROLS. ARE THERE ANY DIFFERENCES? 340
EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome 314
Role of guanylate binding protein-1 in vascular defects associated with chronic inflammatory diseases. 294
The Pathogenicity of Anti-β2GP1-IgG Autoantibodies Depends on Fc Glycosylation 256
Aicardi-Goutieres syndrome, a rare neurological disease in children: a new autoimmune disorder? 233
Long-term outcome of children of rheumatic disease patients 233
Sine causa tetraparesis: A pilot study on its possible relationship with interferon signature analysis and Aicardi Goutières syndrome related genes analysis 233
COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case–control study 215
The role of second trimester uterine artery Doppler in pregnancies with systemic lupus erythematosus 210
Antirheumatic drugs and reproduction in women and men with chronic arthritis. 208
SINDROME DA ANTICORPI ANTIFOSFOLIPIDI E LESIONI PUNTIFORMI DELLA SOSTANZA BIANCA ALLA RISONANZA MAGNETICA. QUAL E' IL LORO SIGNIFICATO? VALUTAZIONE DI 169 PAZIENTI CON MANIFESTAZIONI NEUROLOGICHE 207
14th International Congress on Antiphospholipid Antibodies Task Force report on obstetric antiphospholipid syndrome 205
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy 200
14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends 193
Trichostatin A blocks type I interferon production by activated plasmacytoid dendritic cells. 191
A comprehensive review of the clinical approach to pregnancy and systemic lupus erythematosus 190
First Report of the Italian Registry on Immune-Mediated Congenital Heart Block (Lu.Ne Registry) 189
Effector T-cells are expanded in systemic lupus erythematosus patients with high disease activity and damage indexes 187
Typing TREX1 Gene In Patients With Systemic Lupus Erythematosus. 184
Macrophage activation syndrome in adult systemic lupus erythematosus: Report of seven adult cases from a single Italian rheumatology center 184
Anti-IFI16 antibodies and their relation to disease characteristics in systemic lupus erythematosus. 183
Anti-phospholipid antibodies 182
Anti-cardiolipin and anti-beta2-glycoprotein I antibodies: performance of new commercial ELISA kits. 180
Cardiovascular target organ damage in premenopausal systemic lupus erythematosus patients and in controls: Are there any differences? 180
Children born to SLE and APS mothers 179
Management of thrombotic and obstetric antiphospholipid syndrome: A systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults 178
A 24-month prospective study on the efficacy and safety of two different monthly regimens of vitamin D supplementation in pre-menopausal women with systemic lupus erythematosus 176
Autoantibodies' titre modulation by anti-BlyS treatment in systemic lupus erythematosus. 173
Validity of the rheumatoid arthritis impact of disease (RAID) score and definition of cut-off points for disease activity states in a population-based European cohort of patients with rheumatoid arthritis 171
Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome 171
Antiphospholipid antibodies mediate autoimmunity against dying cells. 169
Association Between Changes in BLyS Levels and the Composition of B and T Cell Compartments in Patients With Refractory Systemic Lupus Erythematosus Treated With Belimumab 169
Longterm outcome of patients with primary antiphospholipid syndrome: A retrospective multicenter study 169
25 years of the antiphospholipid syndrome: lights and shadows on the primary prophylaxis of asymptomatic patients with confirmed positivity of antiphospholipid antibodies. 168
Systemic vasculitis and pregnancy: a multicenter study on maternal and neonatal outcome of 65 prospectively followed pregnancies 168
Inflammatory molecules: A target for treatment of systemic autoimmune diseases. 164
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome 164
Organ damage accrual and distribution in systemic lupus erythematosus patients followed-up for more than 10 years 163
Patients with longstanding primary antiphospholipid syndrome: retrospective analysis of organ damage and mortality 162
Pregnancy implications for systemic lupus erythematosus and the antiphospholipid syndrome 160
The effects of lupus and antiphospholipid antibody syndrome on foetal outcomes 160
Pregnancy in autoimmune rheumatic diseases: the importance of counselling for old and new challenges. 157
Much more than thrombosis and pregnancy loss: the antiphospholipid syndrome as a 'systemic disease'. 157
Lymphopenia as a risk factor for neurologic involvement and organ damage accrual in patients with systemic lupus erythematosus: A multi-center observational study 156
Are the autoimmune/inflammatory syndrome induced by adjuvants (ASIA) and the undifferentiated connective tissue disease (UCTD) related to each other? A case-control study of environmental exposures 155
Risk factors for adverse maternal and fetal outcomes in women with confirmed aPL positivity: Results from a multicenter study of 283 pregnancies 154
Primary anti-phospholipid syndrome: any role for serum complement levels in predicting pregnancy complications? 153
Long-term outcome of children born from mothers with autoimmune diseases 153
Subpopulations of anti-β₂glycoprotein I antibodies with different pathogenic potential: fine specificity against the domains of β₂glycoprotein I 150
Exosome-delivered microRNAs promote IFN-α secretion by human plasmacytoid DCs via TLR7 150
Antiphospholipid antibody profile: implications for the evaluation and management of patients. 149
APS ACTION--AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking. 149
Phenotype modifications of T-cells and their shift toward a Th2 response in patients with systemic lupus erythematosus supplemented with different monthly regimens of vitamin D 149
Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study 149
Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome 149
Anti-inflammatory action of colchicine in hospitalised patients with COVID-19. Response to: 'Colchicine treatment in community healthcare setting to prevent severe COVID-19' by Della-Torre et al 149
Antinucleosome antibodies in primary antiphospholipid syndrome: a hint at systemic autoimmunity? 148
Are the current attempts at standardization of antiphospholipid antibodies still useful? Emerging technologies signal a shift in direction. 148
Autoantibodies against galectins are associated with antiphospholipid syndrome in patients with systemic lupus erythematosus. 148
ANTI-BETA2 GLYCOPROTEIN I-DOMAIN 1 AUTOANTIBODIES: COMPARISON BETWEEN TWO METHODS OF DETECTION 148
State of the art: Reproduction and pregnancy in rheumatic diseases. 148
Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome 148
Beyond the "syndrome": antiphospholipid antibodies as risk factors. 147
European multicentre pilot survey to assess vitamin D status in rheumatoid arthritis patients and early development of a new Patient Reported Outcome questionnaire (D-PRO) 147
Long-term neurodevelopmental outcome of children born to prospectively followed pregnancies of women with systemic lupus erythematosus and/or antiphospholipid syndrome 147
Autoantibodies against galectin-2 peptides as biomarkers for the antiphospholipid syndrome. 146
An EULAR study group pilot study on reliability of simple capillaroscopic definitions to describe capillary morphology in rheumatic diseases 146
EFFICACY AND SAFETY OF CYCLOSPORINE-A DURING PREGNANCY IN AUTOIMMUNE DISEASES 145
Management of recurrent thrombosis in antiphospholipid syndrome 145
Anti-phospholipid IgG antibodies detected by line immunoassay differentiate patients with anti-phospholipid syndrome and other autoimmune diseases 145
PROSPECTIVELY FOLLOWED PREGNANCIES IN PATIENTS WITH SYSTEMIC VASCULITIS: STILL MANY PROBLEMS ON BOTH FOETAL AND MATERNAL SIDE 144
High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: 'PROS' and 'CONS'. 143
Pregnancy in patients with autoimmune disease: A reality in 2016 142
Predictors of maternal and fetal complications in SLE patients: a prospective study 141
Exploring Autoimmunity in a Cohort of Children with Genetically Confirmed Aicardi–Goutières Syndrome 141
Development of automated assays for anticardiolipin antibodies determination: addressing antigen and standardization issues. 140
Clinical significance of IgA anti-cardiolipin and IgA anti-β2glycoprotein I antibodies. 140
Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. 140
Primary antiphospholipid syndrome evolving into systemic lupus erythematosus: may antinucleosome antibodies be predictive? 139
Involvement of renal tubular Toll-like receptor 9 in the development of tubulointerstitial injury in systemic lupus. 137
Characterization of B- and T-Cell Compartment and B-Cell Related Factors Belonging to the TNF/TNFR Superfamily in Patients With Clinically Active Systemic Lupus Erythematosus: Baseline BAFF Serum Levels Are the Strongest Predictor of Response to Belimumab after Twelve Months of Therapy. 137
Neonatal effects of maternal antiphospholipid syndrome. 135
I polimorfismi della metilentetraidrofolatoreduttasi (MTHFR) nel trattamento con methotrexate di pazienti con artrite reumatoide. Revisione della letteratura ed esperienza personale. 135
A PROSPECTIVE STUDY IN PREMENOPAUSAL WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS SUPPLEMENTED WITH TWO DIFFERENT REGIMES OF VITAMIN D: EFFICACY AND SAFETY AT SIX MONTHS OF FOLLOW-UP 135
Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy 134
The 2016 classification criteria for primary Sjogren's syndrome: What's new? 134
Long-term treatment with tocilizumab in giant cell arteritis: efficacy and safety in a monocentric cohort of patients 134
DOMAIN 1 IS THE MAIN SPECIFICITY OF ANTI-BETA2GPI ANTIBODIES IN SYSTEMIC AUTOIMMUNE DISEASES 133
DECREASED TITER OF ANTI-CCP ANTIBODIES AND RHEUMATOID FACTOR AND REDUCTION OF POSTSWITCH MEMORY B CELLS AFTER ABATACEPT TREATMENT FOR RHEUMATOID ARTHRITIS 133
The Efficacy and Safety of Cyclosporin A in Pregnant Patients with Systemic Autoimmune Diseases 132
Infertility in women with systemic autoimmune diseases 132
A multicentre study of 244 pregnancies in undifferentiated connective tissue disease: maternal/fetal outcomes and disease evolution 132
METODICHE AUTOMATIZZATE PER ANTICORPI ANTINUCLEO (ANA): E' POSSIBILE SOSTITUIRE L'IMMUNOFLUORESCENZA INDIRETTA? 131
IL COMPLEMENTO NELLA GRAVIDANZA DI DONNE AFFETTE DA SINDROME DA ANTICORPI ANTIFOSFOLIPIDI PRIMARIA 130
Low levels of vitamin D are common in primary antiphospholipid syndrome with thrombotic disease. 130
Small extracellular vesicle-delivered microRNAs promote IFN-alpha secretion by plasmacytoid DCs via TLR7 130
Vitamin D and antiphospholipid syndrome. 127
Belimumab decreases flare rate and hinders the expected damage progression in patients with active systemic lupus erythematosus 127
Disease course and obstetric outcomes of pregnancies in juvenile idiopathic arthritis: are there any differences among disease subtypes? A single-centre retrospective study of prospectively followed pregnancies in a dedicated pregnancy clinic 125
Refractory obstetrical antiphospholipid syndrome: Features, treatment and outcome in a European multicenter retrospective study 124
Totale 16.427
Salva come PNG Salva come JPEG
Categoria #
all - tutte 152.623
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 152.623
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021176 0 0 0 0 0 0 0 0 0 0 0 176
2021/20221.763 114 280 54 102 20 102 57 132 103 206 172 421
2022/20231.285 248 16 32 58 125 377 5 107 176 4 65 72
2023/20241.814 108 64 144 158 66 345 56 78 456 33 26 280
2024/20254.520 84 71 66 530 408 411 509 247 392 351 915 536
2025/20269.695 856 1.383 744 1.497 911 608 1.351 371 549 869 364 192
Totale 31.720